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Introduction: Systemic sclerosis (SSc) and primary biliary cirrhosis (PBC) are rare polygenic autoimmune diseases
(AIDs) characterized by fibroblast dysfunction. Furthermore, both diseases share some genetic bases with other
AIDs, as evidenced by autoimmune gene pleiotropism. The present study was undertaken to investigate whether
single-nucleotide polymorphisms (SNPs) identified by a large genome-wide association study (GWAS) in PBC might
contribute to SSc susceptibility.
Methods: Sixteen PBC susceptibility SNPs were genotyped in a total of 1,616 patients with SSc and 3,621 healthy
controls from two European populations (France and Italy).
Results: We observed an association between PLCL2 rs1372072 (odds ratio (OR) = 1.22, 95% confidence interval (CI)
1.12 to 1.33, Padj = 7.22 × 10
−5), nuclear factor-kappa-B (NF-κB) rs7665090 (OR = 1.15, 95% CI 1.06 to 1.25, Padj = 0.01), and
IRF8 rs11117432 (OR = 0.75, 95% CI 0.67 to 0.86, Padj = 2.49 × 10
−4) with SSc susceptibility. Furthermore, phenotype
stratification showed an association between rs1372072 and rs11117432 with the limited cutaneous subgroup (lcSSc)
(Padj = 4.45 × 10
−4 and Padj = 0.001), whereas rs7665090 was associated with the diffuse cutaneous subtype (dcSSc)
(Padj = 0.003). Genotype-mRNA expression correlation analysis revealed that the IRF8 protective allele was associated
with increased interferon-gamma (IFN-γ) expression (P = 0.03) in patients with SSc but decreased type I IFN (IFIT1)
expression in patients and controls (P = 0.02). In addition, we found an epistatic interaction between NF-κB and IRF8
(OR = 0.56, 95% CI 0.00 to 0.74, P = 4 × 10−4) which in turn revealed that the IRF8 protective effect is dependent on the
presence of the NF-κB susceptibility allele.
Conclusions: An analysis of pleiotropic genes identified two new susceptibility genes for SSc (NF-κB and PLCL2) and
confirmed the IRF8 locus. Furthermore, the IRF8 variant influenced the IFN signature, and we found an interaction
between IRF8 and NF-κB gene variants that might play a role in SSc susceptibility.* Correspondence: yannick.allanore@cch.aphp.fr
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Systemic sclerosis (SSc) is an autoimmune disease (AID)
characterized by vascular damage, autoantibody produc-
tion, and fibrotic events. SSc is an orphan disease that is
considered the most severe connective tissue disorder,
representing an important medical challenge because of
its debilitating progressive nature [1]. The precise aeti-
ology of the disease remains unclear. However, as in
other AIDs, interactions between environment and gen-
etic factors are thought to play a key role in disease sus-
ceptibility [2]. Indeed, several reports of well-powered
candidate gene studies, together with genome-wide asso-
ciation studies (GWASs), have established numerous
SSc susceptibility genes, including STAT4, IRF5, TNFSF4,
CD226, CD247, and BANK1 [3,4]. The vast majority of
these susceptibility loci belong to pathways involved in
immune responses or inflammation and were identified
in other AIDs [3]. Previous work from our team demon-
strated that polyautoimmunity affects up to a quarter of
patients with SSc, highlighting the concept of shared
autoimmunity in SSc [5]. It is well established that AIDs
encompass a broad range of phenotypic manifestations
and severity, indicating that the effects of these loci are
not of equal magnitude and may not be associated in the
same direction (risk or protection) among different dis-
eases [3]. Fibroblast dysfunction, the SSc hallmark, can
also be observed in primary biliary cirrhosis (PBC). PBC
is a disease marked by progressive destruction of the
liver and can co-occur with SSc, suggesting that these
two AIDs may share common pathways and may be a
result of common-variant loci of weak effect [6]. A re-
cent GWAS carried out in patients with PBC identified
12 new loci involved in disease susceptibility and
highlighted the importance of type I interferon (IFN),
nuclear factor-kappa-B (NF-κB), and Toll-like receptor
(TLR) signaling [7] in its pathogenesis. Given theTable 1 Characteristics of systemic sclerosis patients included
French cohort (n = 1,022)
Age in years, mean ± SD 57.4 ± 13.9
Male gender, number 152
Disease duration in years, mean ± SD 13.1 ± 7.1
lcSSc, percentage 60
dcSSc, percentage 29.5
Lung fibrosis seen on CT, percentage 36.1
FVC <75%, percentage 14
Digital ulcers (ever occurred), percentage 33
ACA+, percentage 32.3
Anti-topo I+, percentage 23
Associated AID, percentage 15
ACA, anti-centromere antibody; anti-topo I, anti-topoisomerase antibody; associated
dcSSc, diffuse cutaneous systemic sclerosis; FVC, forced vital capacity; lcSSc, limitedevidence of shared autoimmune genes between SSc and
other AIDs, we investigated the association of 16
single-nucleotide polymorphisms (SNPs), recently iden-
tified as susceptibility factors for PBC, with SSc and its
subphenotypes.Methods
Study population
We performed a case-control association study with a
European Caucasian cohort consisting of 1,616 patients
with SSc (1,022 French and 594 Italians) and 3,621 con-
trols (2,384 French and 1,237 Italians). Only individuals
with European ancestry (defined as all four grandparents
being of European Caucasian ancestry) were included in
the study. This cohort has already been used in several
previous genetic studies, and high homogeneity between
French and Italian samples has been demonstrated [4,8].
Control subjects were age- and sex-matched to patients
with SSc. The characteristics of the patients with SSc are
shown in Table 1. All patients with SSc were classified
by LeRoy’s cutaneous subtype and were phenotypically
screened for anti-nuclear antibodies and pulmonary
fibrosis (PF). The latter was defined as any of the follow-
ing changes on computed tomography scan, such as in
our previous studies: reticulations, honeycombing, and
traction. In line with all of our previous projects,
patients with SSc were also evaluated for the presence of
other potential AIDs. To avoid any bias due to a possible
excess of the risk alleles attributable to these patients, 23
SSc patients showing PBC co-occurrence were excluded
from the main study. This study was approved by the
Comité Consultatif de Protection des Personnes dans la
Recherche Biomédicale (CCPPRB) Paris Cochin (dossier
2068). All participants enrolled in this study provided
written informed consent.in the study
Italian cohort (n = 594) Combined cohort (n = 1,616)
48.8 ± 13.4 53.1 ± 13.6
55 207
12.4 ± 8.7 12.75 ± 7.9
74.7 64.4
25.2 28
34.6 35.3
16.1 14.6
44 36.6
44.6 36.6
32.6 26.3
14.6 15
AID, at least one associated autoimmune disease; CT, computed tomography;
cutaneous systemic sclerosis; SD, standard deviation.
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The SNP selection was based on a previous PBC GWAS,
which identified these SNPs as susceptibility genes to PBC
[7]. Among these candidates, two SNPs, STAT4 rs10931468
and IRF5 rs12531711, located in loci reproducibly strongly
associated with SSc in several studies [3,4], were excluded
from the study. The list of the selected SNPs, as well as in-
formation about their localization and putative function, is
shown in Additional file 1: Table S1.
Genotyping
DNA samples from SSc patients and controls were ge-
notyped for the 16 tag SNPs: rs10752747, rs12134279,
rs1372072, rs2293370, rs485499, rs7665090, rs860413,
rs6974491, rs6421571, rs1800693, rs911263, rs8017161,
rs11117432, rs7208487, rs3745516, and rs968451. Geno-
typing was performed by using a competitive allele-specific
polymerase chain reaction system (KASpar genotyping;
KBioscience, Hoddesdon, UK).
Gene expression in peripheral blood mononuclear cells
To assess a possible genotype-phenotype correlation, we
selected the three associated genes—PLCL2, NFKB1, and
IRF8—to perform gene expression assays of their mRNA.
Moreover, because of compelling data on IRF8-associated
pathways, we also investigated IFN-γ and type I IFN
(IFIT1) mRNA gene expression. We randomly selected
peripheral blood nuclear cell (PBMC) samples from 39 pa-
tients (who did not receive immunosuppressive drugs)
and 24 healthy controls. The total RNA was obtained by
using an RNA extraction kit (RNeasy Mini Kit; Qiagen,
Hilden, Germany) followed by a c-DNA reverse transcrip-
tion step (SuperScript II Reverse Transcriptase; Invitrogen,
Waltham, MA, USA). Gene expression was performed
by using quantitative Real-Time Polymerase Reaction
(Universal Master Mix II; Applied Biosystems, Waltham,
MA, USA). All primers were obtained by a predesigned
gene expression assay (Applied Biosystems).
Statistical analysis
Statistical analyses were performed by using PLINK
(Harvard and MIT version 1.07, available at [9]). Power
calculation was assessed by using a two independent
binomial module combined with a one-sided Fisher
exact test (StatXact 8 software; Cytel, Cambridge, MA,
USA). Tests for conformity with Hardy-Weinberg
equilibrium were performed by using a standard
chi-square test (1 degree of freedom). Homogeneity
between the two cohorts was confirmed by using the
Breslow-Day method and therefore the combined data
were subsequently analyzed by calculating the pooled
odds ratios (ORs) by using a Cochran-Mantel-Haenszel
test under fixed effects. Individual association analyses
of all SNPs were performed by comparing cases andcontrols with a two-sided Fisher exact test on allelic dis-
tribution. All ORs are provided with their 95% confi-
dence intervals (CIs).
To test SNP × SNP epistasis, the allele frequencies were
compared in patients and control subjects. The PLCL2*T
alleles, NF-kB*G alleles, and IRF8*A alleles were considered
binary random variables, and the dependency of disease on
pairwise combinations of these covariates was tested with a
logistic regression model. The fitted model included each
one of two tested factors as first-order components and an
interaction term reflecting the extent of the allelic by
allelic epistasis. We applied a logistic regression assuming
a double-dominant model. Exact calculations of ORs and
P values were made with Logxact 8 software (Cytel).
We applied the Bonferroni correction although it is very
conservative; 16 tag SNPs were considered to test the
association between each SNP and SSc (P values were
therefore multiplied by 16 to get the adjusted ones). For
disease phenotypes correction, we took into account seven
subtypes (P values were multiplied by 7 to get the adjusted
ones). An unpaired two-sided t test was used for mRNA
expression levels analysis. An adjusted P value of less than
0.05 was considered statistically significant.
Results
Single-marker analysis
Sixteen SNPs were genotyped in two European popula-
tions (French and Italian). Among the SNPs of interest,
minor allele frequencies (MAFs) range from 11% to 44%;
therefore, we provide a power calculation for these two
MAFs. For an 11% MAF, our power to detect an associ-
ation is more than 99% for an OR of 1.5 and is 81% to
detect an OR of 1.3. For a 44% MAF, our power is more
than 99% to detect an OR of 1.3 or higher. Genotype
frequencies were in Hardy-Weinberg equilibrium in the
control population for all of the SNPs investigated.
We first evaluated the French sample and observed six
loci for which a nominal P value was reached: PLCL2
rs1372072 OR = 1.22, 95% CI 1.10 to 1.36, P = 1.97 × 10−4;
TIMMDC1 rs2293370 OR= 0.84, 95% CI 0.73 to 0.96,
P = 1.46 × 10−2; IL12A rs485499 OR = 0.88, 95% CI 0.79 to
0.99, P = 3.37 × 10−2; NF-kB rs7665090 OR = 1.12, 95% CI
1.01 to 1.25, P = 2.47 × 10−2; IL7R rs860413 OR = 0.89,
95% CI 0.79 to 1.00, P = 5.77 × 10−2; and IRF8 rs11117432
OR= 0.68, 95% CI 0.68 to 0.93, P = 6.52 × 10−3. We then
analysed all the SNPs in the Italian sample and observed
that five SNPs, including three previously identified in
the French sample, were associated with SSc: PLCL2
rs1372072 OR = 1.22, 95% CI 1.05 to 1.41, P = 7.76 × 10−3;
NF-kB rs7665090 OR = 1.20, 95% CI 1.04 to 1.38,
P = 9.00 × 10−3; ELMO1 rs6974491 OR= 1.27, 95% CI 1.04
to 1.55, P = 1.93 × 10−2; RAD51B rs911263 OR = 0.80, 95%
CI 0.69 to 0.93, P = 4.18 × 10−3; and IRF8 rs11117432
OR= 0.70, 95% CI 0.57 to 0.85, P = 5.48 × 19−4. It is of
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population, only PLCL2 rs1372072 P = 3 × 10−3 and IRF8
rs11117432 OR = 0.68, 95% CI 0.68 to 0.93, P = 8.76 × 10−3
remained significant in French and Italian samples, re-
spectively (Table 2).
Therefore, to increase the statistical power, we moved for
combined analyses taking into account that homogeneity of
the cohorts was confirmed by the Breslow-Day test (no
evidence of interpopulation heterogeneity) (Table 3). Our
combined analysis revealed a significant association for three
of the studied SNPs: PLCL2 rs1372072 OR= 1.22, 95% CI
1.12 to 1.33, Padj = 7.22 × 10
−5; NF-kB rs7665090 OR= 1.15,
95% CI 1.06 to 1.25, Padj = 0.01; and IRF8 rs11117432,
OR= 0.75, 95% CI 0.67 to 0.86, Padj = 2.49 × 10
−4 (Table 3).
It is noteworthy that combined analyses revealed the same
directions of effect for the three SNPs and, of the most
importance, that the combined P value was greater than the
P value observed in a single population, altogether, this
supports a true association.
The next step was to investigate possible associations
between PLCL2, IRF8, and NF-κB polymorphisms with
clinical features. For that purpose, we stratified the
patients according to their main subphenotypes in the
combined sample. After Bonferroni correction for
multiple testing, we found that the variants PLCL2
rs1372072 and IRF8 rs11117432 were associated with
the limited cutaneous subgroup (lcSSc) (OR = 1.23, 95% CI
1.11 to 1.36, Padj = 4.45 × 10
−4 and OR= 0.75, 95% CI 0.65
to 0.87, Padj = 0.001, respectively) and with the presence of
anti-centromere antibodies (ACAs) (OR = 1.29, 95% CI
1.13 to 1.46, Padj = 4.35 × 10
−4 and OR= 0.78, 95% CI 0.65
to 0.93, Padj = 0.04) (Table 3).
The NF-κB variant rs7665090 was shown to be associ-
ated with patients belonging to a diffuse cutaneous pheno-
type (dcSSc) (OR = 1.28, 95% CI 1.11 to 1.47, Padj = 0.003)
and also with the PF subset (OR = 1.24, 95% CI 1.09 to
1.41, Padj = 0.004) (Table 3). No association was found be-
tween the DENND1B, TIMMDC1, IL7R, ELMO1, DDX6,
TNFRSF1A, RAD51B, TNFAIP2, SPIB, and SNORD43
gene variants and SSc (Additional file 2: Table S2).
When the 23 SSc-PBC patients were analysed separately,
no significant association was observed when they were
compared with the 3,621 controls for any SNPs; furthermore,
their addition to the whole sample (23 SSc-PBC + 1,628
SSc patients) did not modify the results (significant associ-
ation for PLCL2, IRF8, and NF-κB, with unchanged magni-
tude of the effects). In regard to the group of SSc patients
having another AID (n = 224), single-marker analyses
revealed significant association with PLCL2 rs1372072 only
(P = 0.001; OR = 1.375, 95% CI 1.13 to 1.67).
Follow-up of the raised hypotheses for single markers
SNPs belonging to the genes highlighted herein have been
previously reported as associated or with a trend forassociation in previous works. For some genes highlighted
in our study, some variants not primarily herein studied
have been reported as associated with SSc or as having a
trend for association with SSc. Indeed, Martin et al. [10]
reported a suggestive association of NF-κB rs1598859,
and a robust association has been reported for IRF8
rs11642873 [11]. Furthermore, a recent work did suggest
some association in two loci for which we herein identified
a nominal association but not reaching significance after
multi-test correction as we observe for DDX6 rs7130875
and IL12A rs77583790 [12].
In our sample, we therefore investigated these markers
and compared the association with the one observed with
our newly identified SNPs. To that end, we used a subset of
our patients for whom we have performed genome-wide
typing in the past (sample of 564 patients with SSc and 488
healthy controls) [13]. In regard to NF-κB, we first observed
in HapMap that rs1598859 and rs7665090 are not in
complete linkage disequilibrium (LD) (D′ = 0.77 and
R2 = 0.31; SNPs are on the same block according to D′
value but are not in phase according to R2) and then found
from our GWAS data that the MAFs were 0.355 in patients
with SSc and 0.382 in controls (uncorrected P value = 0.2).
For IRF8, an established locus, we first observed that
rs11642873 and rs11117432 are not in complete LD
(D′ = 0.707 and R2 = 0.456). Within our subset with GWAS
data, we identified that the rs11642873 MAFs were 0.14 in
the patients with SSc and 0.174 in the controls
(P value = 0.034 without correction; OR = 0.772, 95% CI
0.61 to 0.98). The P value is less significant than the one
obtained for rs11117432 in the same subset (MAF = 0.156
versus 0.213; P = 0.0008), and the OR also shows a weaker
effect (OR = 0.68, 95% CI 0.55 to 0.85). We also performed
haplotype analyses to estimate the effects of the two SNPs
and that relates to conditional analyses; we observed that
the haplotype combination including the single rs11642873
risk variant (CG haplotype) was not associated with SSc
risk (frequency of 0.108 versus 0.117; P = 0.499) but that
the haplotype combination including the single rs11117432
risk variant (AA haplotype) was significantly associated
with SSc risk (0.124 versus 0.156; P = 0.032). We proceeded
similarly for DDX6 rs7130875 and observed that it was not
in LD with rs6421571 (D′ = 0.839 and R2 = 0.084). DDX6
rs7130875 was not included in our array, but we used the
perfect proxy rs4499035 and identified that the MAFs were
0.261 in patients with SSc and 0.252 in the controls
(uncorrected P value = 0.69). IL12A rs77583790 SNP was
not included in the array used in our GWAS, and no
accurate imputation could be done. Therefore, we have
performed a dedicated genotyping by using the TaqMan
method in a subset of the patients and controls for whom
DNA was still available and who did participate in the
present study; we found that rs77583790 minor A allele
was present in 2.33% of 1,585 patients with SSc and in
Table 2 Analysis of PLCL2 rs1372072, NF-κB rs7665090, and IRF8 rs11117432 gene variants in French and Italian
populations
SNP, phenotype (n) MAF Genotype distribution P value Padj
a OR (95% CI)
French Caucasian
PLCL2 rs1372072 T TT (%) TC (%) CC (%)
SSc (1,021) 0.39 15.40 47.41 37.17 1.97 × 10−4 3.15 × 10−3 1.22 (1.10-1.36)
dcSSc (298) 0.39 15.64 46.93 37.41 0.02 0.39 1.22 (1.03-1.46)
SSc. Topo I+ (233) 0.39 15.51 48.27 36.20 0.02 0.39 1.25 (1.03-1.52)
lcSSc (591) 0.38 15.29 47.07 37.62 4.45 × 10−3 0.07 1.21 (1.06-1.38)
SSc. ACA+ (349) 0.39 16.90 45.77 37.31 5.37 × 10−3 0.08 1.26 (1.07-1.49)
Pulmonary fibrosis (364) 0.40 16.62 48.47 34.90 6.97 × 10−4 0.01 1.32 (1.12-1.55)
Controls (2,384) 0.34 12.31 44.01 43.67 NA NA NA
NF-κB rs7665090 G GG (%) AG (%) AA (%)
SSc (1,021) 0.52 27.21 49.59 23.18 0.02 0.39 1.12 (1.01-1.25)
dcSSc (298) 0.54 32.29 44.79 22.91 0.01 0.16 1.25 (1.05-1.49)
SSc. Topo I+ (233) 0.54 31.14 47.36 21.49 0.01 0.29 1.26 (1.04-1.53)
lcSSc (591) 0.50 24.95 51.81 23.22 0.26 NS 1.07 (0.94-1.22)
SSc. ACA+ (349) 0.50 23.97 52.04 23.97 0.65 NS 1.04 (0.88-1.22)
Pulmonary fibrosis (364) 0.52 28.53 48.87 22.59 0.05 0.84 1.17 (1.00-1.37)
Controls (2,384) 0.49 23.35 51.31 25.33 NA NA NA
IRF8 rs11117432 A AA (%) AG (%) GG (%)
SSc (1,021) 0.16 2.53 27.28 70.18 6.52 × 10−3 0.10 0.79 (0.68-0.93)
dcSSc (298) 0.15 2.38 25.25 72.35 0.01 0.22 0.73 (0.56-0.94)
SSc. Topo I+ (233) 0.16 3.52 26.87 69.60 0.23 NS 0.84 (0.64-1.10)
lcSSc (591) 0.16 2.28 29.22 68.48 0.08 NS 0.84 (0.69-1.01)
SSc. ACA+ (349) 0.15 3.28 25.37 71.34 0.04 0.74 0.78 (0.62-0.99)
Pulmonary fibrosis (364) 0.16 2.26 27.76 69.97 0.05 0.82 0.79 (0.63-1.00)
Controls (2,384) 0.19 3.77 31.33 64.88 NA NA NA
Italian Caucasian
PLCL2 rs1372072 T TT (%) TC (%) CC (%)
SSc (607) 0.36 13.36 47.03 39.59 7.76 × 10−3 0.12 1.22 (1.05-1.41)
dcSSc (152) 0.34 11.72 46.20 42.06 0.42 NS 1.11 (0.86-1.44)
SSc. Topo I+ (233) 0.35 11.57 47.36 41.05 0.29 NS 1.13 (0.90-1.42)
lcSSc (455) 0.37 13.90 47.30 38.78 5.55 × 10−3 0.08 1.25 (1.06-1.47)
SSc. ACA+ (349) 0.38 14.66 48.49 36.84 4.49 × 10−3 0.07 1.32 (1.09-1.61)
Pulmonary fibrosis (210) 0.39 13.72 50.98 35.29 7.62 × 10−3 0.12 1.34 (1.08-1.67)
Controls (1,237) 0.32 10.68 43.41 45.89 NA NA NA
NF-κB rs7665090 G GG (%) AG (%) AA (%)
SSc (607) 0.52 29.66 47.45 24.23 9.00 × 10−3 0.14 1.20 (1.08-1.33)
dcSSc (152) 0.55 33.33 44.02 22.66 0.01 0.31 1.34 (1.03-1.76)
SSc. Topo I+ (233) 0.50 24.61 51.79 23.58 0.38 NS 1.10 (0.81-1.37)
lcSSc (455) 0.51 27.90 47.76 24.33 0.05 0.89 1.16 (0.96-1.34)
SSc. ACA+ (349) 0.51 27.50 47.58 24.90 0.18 NS 1.14 (0.95-1.34)
Pulmonary fibrosis (210) 0.56 34.61 42.78 22.59 2.29 × 10−3 0.04 1.37 (1.17-1.68)
Controls (1,237) 0.48 22.60 50.85 26.53 NA NA NA
IRF8 rs11117432 A AA (%) AG (%) GG (%)
Arismendi et al. Arthritis Research & Therapy  (2015) 17:71 Page 5 of 11
Table 2 Analysis of PLCL2 rs1372072, NF-κB rs7665090, and IRF8 rs11117432 gene variants in French and Italian
populations (Continued)
SSc (607) 0.12 1.17 23.23 75.58 5.47 × 10−4 8.76 × 10−3 0.70 (0.57-0.85)
dcSSc (152) 0.14 2.64 24.50 72.84 0.33 NS 0.83 (0.60-1.17)
SSc. Topo I+ (233) 0.12 2.04 21.42 76.53 0.02 0.44 0.70 (0.51-0.96)
lcSSc (455) 0.12 0.67 22.79 76.52 2.51 × 10−4 4 × 10−3 0.65 (0.52-0.82)
SSc. ACA+ (349) 0.13 1.14 25.47 73.38 0.06 0.97 0.77 (0.59-1.01)
Pulmonary fibrosis (210) 0.12 1.92 22.11 75.96 0.03 0.51 0.71 (0.52-0.96)
Controls (1,237) 0.17 3.15 28.21 68.63 NA NA NA
aAfter Bonferroni correction. ACA+, anti-centromere antibody; CI, confidence interval; dcSSc, diffuse cutaneous systemic sclerosis; lcSSc, limited cutaneous systemic
sclerosis; MAF, minor allele frequency; n, number of pooled patients analysed; NA, not applicable; NS, not significant; OR, odds ratio; SNP, single-nucleotide polymorphism;
SSc, systemic sclerosis; Topo I+, anti-topoisomerase I antibody.
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ation but not supporting any correction for multiple testing
(uncorrected P = 0.04). We have thereafter performed some
meta-analysis by using the data included in the cited works
[10-12] together with ours, thanks to Pr Javier Martin, who
provided the genotypic data from his original studies (theTable 3 Analysis of PLCL2 rs1372072, NF-κB rs7665090, and IR
populations (French and Italian)
SNP, phenotype (n) MAF Genotype distribution
PLCL2 rs1372072 T TT (%) TC (%)
SSc (1,597) 0.38 14.65 47.27
dcSSc (439) 0.38 14.35 46.69
SSc, Topo I+ (422) 0.38 13.74 47.86
lcSSc (1,028) 0.38 14.68 47.17
SSc, ACA+ (609) 0.39 15.92 46.96
Pulmonary fibrosis (565) 0.40 15.57 49.38
Controls (3,570) 0.33 11.76 43.80
NF-κB rs7665090 G GG (%) AG (%)
SSc (1,590) 0.52 27.98 48.55
dcSSc (438) 0.55 32.64 44.52
SSc, Topo I+ (423) 0.53 28.13 49.40
lcSSc (1,025) 0.51 26.24 50.04
SSc, ACA+ (611) 0.51 25.53 50.08
Pulmonary fibrosis (562) 0.54 30.78 46.61
Controls (3,585) 0.48 23.09 51.15
IRF8 rs11117432 A AA (%) AG (%)
SSc (1,500) 0.14 2.03 25.76
dcSSc (444) 0.15 2.47 25
SSc, Topo I+ (423) 0.15 2.83 24.34
lcSSc (1,011) 0.14 1.58 26.40
SSc, ACA+ (598) 0.15 2.34 25.41
Pulmonary fibrosis (561) 0.15 2.13 25.66
Controls (2,290) 0.18 3.44 29.69
aAfter Bonferroni correction. ACA+, anti-centromere antibody; CI, confidence inte
systemic sclerosis; MAF, minor allele frequency; n, number of pooled patients analysed
polymorphism; SSc, systemic sclerosis; Topo I+, anti-topoisomerase I antibody.sample size was not always the same as in the original study
which could include several cohorts from various origins).
As shown in Additional file 3: Table S3, neither the P value
nor the OR was improved for NF-κB, DDX6, and IL12A
genes. This suggests that adding our data does not
strengthen the previous findings and does not support aF8 rs11117432 gene variants in the combined Caucasian
P value Padj
a OR (95% CI)
CC (%)
38.07 4.01 × 10−6 7.22 × 10−5 1.22 (1.12-1.33)
38.95 0.01 0.12 1.19 (1.03-1.37)
38.38 0.01 0.09 1.20 (1.03-1.39)
38.13 6.37 × 10−5 4.45 × 10−4 1.23 (1.11-1.36)
37.11 6.21 × 10−5 4.35 × 10−4 1.29 (1.13-1.46)
35.04 1.29 × 10−5 9.07 × 10−5 1.33 (1.17-1.51)
44.42 NA NA NA
AA (%)
23.45 7.19 × 10−4 0.01 1.15 (1.06-1.25)
22.83 4.93 × 10−4 0.003 1.28 (1.11-1.47)
22.45 0.01 0.12 1.18 (1.03-1.37)
23.70 0.03 0.24 1.11 (1.00-1.22)
24.38 0.20 NS 1.08 (0.95-1.22)
22.59 7.14 × 10−4 0.004 1.24 (1.09-1.41)
25.74 NA NA NA
GG (%)
72.22 1.56 × 10−5 2.49 × 10−4 0.75 (0.67-0.86)
72.52 0.009 0.06 0.76 (0.62-0.93)
72.81 0.01 0.11 0.77 (0.63-0.95)
72.00 1.96 × 10−4 0.001 0.75 (0.65-0.87)
72.24 0.005 0.04 0.78 (0.65-0.93)
72.19 0.004 0.02 0.76 (0.63-0.91)
66.85 NA NA NA
rval; dcSSc, diffuse cutaneous systemic sclerosis; lcSSc, limited cutaneous
; NA, not applicable; NS, not significant; OR, odds ratio; SNP, single-nucleotide
Arismendi et al. Arthritis Research & Therapy  (2015) 17:71 Page 7 of 11significant association for NF-κB rs1598859 and DDX6
rs7130875. In regard to IL12A rs77583790, our results
do not provide an independent replication; however,
the meta-analysis shows a more significant P value
when the French population is added, suggesting that
this locus is further confirmed by our data. For IRF8
rs11642873, our data decrease the P value, and
although the OR is unchanged, the CI is reduced,
suggesting that the association is both stronger and of
higher magnitude (Additional file 3: Table S3).Joint effects of PLCL2, NF-κB, and IRF8 risk alleles on
systemic sclerosis susceptibility
We then investigated the joint effects of PLCL2
rs1372072*T, NF-κB rs7665090*G, and IRF8 rs1117432*A
risk alleles on SSc susceptibility. The ORs for SSc were
0.74 (95% CI 0.62 to 0.90) for carriers of one or two
risk alleles, 0.94 (95% CI 0.79 to 1.11) for carriers of three
risk alleles, 0.88 (95% CI 0.77 to 1.01) for carriers of four
alleles, 1.19 (95% CI 1.03 to 1.38) for carriers of five alleles,
and 1.70 (95% CI 1.32 to 2.19) for carriers of six risk
alleles. Figure 1 shows the ORs for SSc patients with one
or two and three to six risk alleles. Our results demon-
strate that the risk of SSc increases proportionally as the
number of alleles increases, with an OR of 1.70 when six
risk alleles are considered (Figure 1).Figure 1 Joint effects analysis of IRF8, NF-κB, and PLCL2 risk
alleles on systemic sclerosis (SSc) susceptibility. Joint effects of
PLCL2 rs1372072, NF-κB rs7665090, and IRF8 rs11117432 risk alleles
on SSc susceptibility. Values for the number of risk alleles are taken
randomly amongst the genotypes, meaning that a homozygous
patient for one single-nucleotide polymorphism counts for two
alleles even if only one gene is represented. The results of a linear
regression analysis show a multiplicative effect of the alleles on SSc
susceptibility. The odds ratios (ORs) with 95% confidence intervals
are shown as a function of the number of risk alleles of SSc. The
slope of the line corresponds to a 1.20-fold increase in the OR for
each additional risk allele. (OR is provided as a log2 scale).Genetic interaction between associated single-nucleotide
polymorphisms
To investigate possible gene-gene interactions between
the associated SNPs, we applied a logistic regression
(multivariate analysis) on PLCL2 rs1372072*T, NF-κB
rs7665090*G, and IRF8 rs1117432*A alleles. Of the most
interest, we found an epistatic interaction between IRF8
and NF-κB (OR = 0.56, 95% CI 0.00 to 0.74, P = 4 × 10−4),
which in turn demonstrated that the protective effect of
the IRF8 A allele is revealed when the NF-κB G allele is
present (Figure 2A and B). Indeed, when patients were
stratified according to the presence of susceptibility alleles
A and G, we confirmed that the IRF8 A protective effect is
dependent on the presence of the NF-κB G allele (NF-κB
GG or AG: OR = 0.66, 95% CI 0.57 to 0.77, P = 5.91 × 10−8
and NF-κB AA: OR = 1.10, 95% CI 0.85 to 1.41, P = 0.45).
Consistent with that, NF-κB risk OR was observed only
in patients without the protective allele of IRF8 A (IRF8
GG: OR = 1.23, 95% CI 1.10 to 1.38, P = 1 × 10−4 and IRF8
AA or AG: OR = 0.93, 95% CI 0.79 to 1.11, P = 0.46)
(Figure 2C).
mRNA expression
We then investigated the potential influence of the three
associated gene variants PLCL2, NF-κB, and IRF8 on
their mRNA expression levels in 38 patients with SSc
and 24 controls. After stratification according to the
various genotypes, we observed no genotype-phenotype
correlation. However, we further analyzed a possible ef-
fect of the variant IRF8 rs11117432 on IFIT1 and IFN-γ
mRNA relative expression in the same 38 patients with
SSc (nine of them with the IRF8 rs11117432 AA or GA
genotypes and 29 with the GG genotype) and 24 con-
trols (12 with the IRF8 rs11117432 AA or GA genotypes
and 12 with the GG genotype) according to the pub-
lished data on IRF8 effects on IFN signature. Using a
multiple linear regression test, we found out that the
IRF8 rs11117432*A allele was associated with IFIT1
mRNA expression levels independently of the status of
the included individuals (P = 0.022, data not shown).
When all individuals were considered, our results
demonstrated that the IRF8 rs11117432*A variant was
associated with decreased levels of IFIT1 mRNA expres-
sion (P = 0.02). When patients and controls were consid-
ered separately, a trend was observed in the comparison
of the IRF8 rs11117432*A carriers with the non-carriers
(P = 0.10 for patients, P = 0.06) (Figure 3A). We also
observed increased levels of IFN-γ mRNA expression in
SSc patient carriers of IRF8 rs11117432*A when compared
with the non-carriers (P = 0.03) with a trend for difference
for the whole group (P = 0.11) but no difference in
controls (P = 0.35) (Figure 3B). There was no effect of the
epistatic interaction on IFIT1 or IFN-γ expression
(P = 0.59 for IFIT1 and P = 0.50 for IFN-γ).
Figure 2 Analysis of the interaction between IRF8 (A) and NF-κB (G) alleles. (A) Odds ratios (ORs) and 95% confidence intervals attributed to IRF8
rs11117432 A and NF-κB rs7665090 G single-nucleotide polymorphisms (SNPs) after systemic sclerosis (SSc) association analysis. (B) Individual effect of
IRF8 A and NF-κB G compared with the combined effect of both SNPs after logistic regression analysis, demonstrating that the protective effect of IRF8 A
is observed only when NF-κB G is present. The black column represents the group of patients carrying IRF8 (A) allele who did not carry NF-kB (G) allele,
indicating a risk effect for IRF8 (A) (OR = 1.15). The grey column represents patients only harboring NF-kB (G) allele (OR = 1.35). The red column represents
the group of patients who carried IRF8 (A) and NF-kB (G) at the same time, indicating that the protective effect of IRF8 (A) is observed only when NF-κB (G)
is present (OR = 0.56). (C) Analysis of the effect of the susceptible alleles in patients stratified by the presence of NF-KB G or IRF8 A. (OR is provided as a
log2 scale.) ***P <0.05.
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The present study identified NF-κB and PLCL2 as new
SSc susceptibility genes and confirmed the IRF8 locus.
We also showed potential effects on the IFN signature
in regard to the IRF8 gene variant and an interaction
between IRF8 and NF-κB genes.
Our results corroborate previously reported associations
in regard to the IRF8 gene and SSc susceptibility. Here, we
demonstrate, for the first time, the specific association
between IRF8 rs11117432 SNP and SSc susceptibility and
provide data suggesting a stronger association for
rs11117432 as compared with rs11642873, although our
meta-analysis results strengthen the previous findings for
this marker [11]. Indeed, our haplotype analyses further
confirm a stronger association for rs11117432 for a subset
of our patients, but a denser genotyping would be required
to better narrow a potential causal variant. IRF8 is a
nuclear protein, which upon stimulation by pathogen-
associated molecular pattern molecules (PAMPs) movesinto the cytoplasm and activates NF-κB and TLR signaling
pathways, leading to cytokine production and thereby
regulating inflammatory responses [14]. The consequences
of unregulated inflammation are associated with the
development of pathologic fibrosis such as that seen in
SSc [15]. Here, we show that the variant IRF8 rs11117432
increases IFN-γ but decreases IFIT1 gene expression.
Despite reaching significance, our results show subtle
differences, and given the complex regulation of protein
synthesis and activity, more work is required to confirm the
functional impacts of the IRF8 variant. IFNs are a group of
cytokines that play an important role in the regulation of
inflammation [16]. Type I IFNs, such as IFIT1, seem to con-
tribute to the upregulation of TLR-induced inflammation
and transforming growth factor-beta (TGF-β)-responsive
genes expressed by fibroblasts, whereas IFN-γ is a potent
suppressor of the pro-inflammatory TGF-β signaling
pathway, which in turn reduces the production of collagen
I synthesis critical to sustain profibrotic processes in the
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Figure 3 Type I interferon (IFIT1) and interferon-gamma (IFN-γ)
mRNA expression levels in patients with systemic sclerosis (SSc)
and healthy controls. (A) Influence of IRF8 genotype on IFIT1 mRNA
expression in peripheral blood nuclear cells (PBMCs) from patients
with SSc and healthy controls (mean ± standard deviation values;
uncorrected P values). Expression of IFIT1 mRNA was decreased in
carriers of the rs11117432 A allele as compared with non-carriers of
the A allele. Vertical bars indicate the means. (B) Influence of IRF8
genotype on IFN-γ mRNA expression in PBMCs from patients with
SSc and healthy controls. Expression of IFN-γ mRNA was increased in
SSc patient carriers of the rs11117432 A allele as compared with
non-carriers of the A allele. Vertical bars indicate the means.
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agreement with the role played by those specific cytokines
and support the protective role of the IRF8 rs11117432
variant. Thus, IRF8 polymorphisms might have an effect on
pro- and anti-inflammatory modulation, along with regula-
tion of the extracellular matrix, and collagen deposition in
fibrotic diseases. A recent study of serologic and cytokine
profiles in patients with systemic lupus erythematosus also
demonstrated an association between an IRF8 variant
(rs17445836) and decreased levels of IFIT1 [20]. Moreover,according to HapMap data, the SNPs rs11117432 and
rs17445836 are located in a regulatory region, underlying
potential functional effects of those SNPs. In SSc, IRF8
SNPs rs11642873 and rs2280381 were already reported as
being associated with disease susceptibility. It must be
pointed out that rs11117432 and rs2280381 belong to the
same block of LD, suggesting a strong association between
the IRF8 region and SSc [11,21]. Of interest, we also
identified that the association was preferentially observed in
the lcSSc subset and its usual associated anti-nuclear
auto-antibody (anti-centromere), suggesting a potential role
for the pathogenesis in this subgroup of patients.
Epidemiological studies indicate that lcSSc and anti-
centromere-positive patients are often associated with other
AIDs, including secondary Sjögren thyroiditis and PBC,
where IFIT1 is known to play a critical role [5,6].
As a complex polygenic AID, SSc is thought to have
innumerous genes play a role in its aetiology and hetero-
geneity. However, only a handful of genes have been
identified as SSc risk variants. Moreover, these variants
confer relatively small increments in risk and might
explain only a small proportion of the trait heritability,
suggesting that other loci remain to be discovered. Here,
we describe for the first time the association between
NF-κB rs7665090 and SSc susceptibility. A previous work
suggested that NF-κB rs1598859 had a suggestive associ-
ation with SSc [10]; our results do support such an associ-
ation after the analyses of a subset of our sample and by
the performance of a meta-analysis combining our results
together with the previously reported ones [10]. NF-κB is
present in the cytoplasm of virtually all cell types in an
active form associated with the inhibitory κB (IκB) and
has a key role in primarily immune responses related to
antigen recognition, being commonly associated with the
development of autoimmune and chronic inflammatory
diseases [22]. Of interest, the dysregulation of NF-κB
activity has already been implicated in the pathogenesis of
systemic lupus erythematosus [23]. In SSc, the functional
implications of NF-κB polymorphisms are still unclear. The
analysis of NF-κB rs7665090 variant demonstrated no effect
on the levels of NF-κB mRNA expression; this is a
false-negative result, which may have been due to the small
sample size of PBMCs obtained from individuals with SSc.
Further studies with a larger sample size might better
elucidate the influence of NF-κB rs7665090 variant in gene
expression patterns. It is worth mentioning that, in a
previous work, our group identified an association between
TNIP1 and TNFAIP3 with SSc, genes that are known
negative regulators of the NF-κB signaling pathway,
suggesting that NF-κB disturbances might have a role in
SSc susceptibility [13].
Our single-marker analyses also revealed an association
of PLCL2 rs1372072 (OR = 1.23, 95% CI 1.12 to 1.33,
Padj = 7.22 × 10
−5) with SSc. Phospholipase C (PLC)
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kinase C signaling pathway known to be expressed in
hematopoietic cells, which play a role in B-cell receptor
signaling and other immune responses [24]. The PLCL2
rs4535211 variant has been reported in RA and psoriatic
arthritis. The variant was associated with RA risk, whereas
in psoriatic arthritis it was found to be protective [25,26].
According to HapMap data, rs1372072 and rs4535211 are
in high LD (D′ = 0.90) in a block that contains the PLCL2
gene although not in phase (R2 = 0.44). Therefore, our
findings imply that this locus might contribute to several
AIDs; this is an observation that must be confirmed by
denser mapping and additional functional experiments to
further increase our understanding of the role of PLCL2 in
AIDs and SSc.
We followed up two other genes (DDX6 and IL12A) for
which signals of association with SSc were recently de-
scribed by another study [12] and because we observed for
these 2 genes a nominal association in the first step of our
own study for variants harbored by the same genes even if
the results of the first step were not confirmed in our com-
bined analyses. For these additional SNPs that are a com-
mon variant of DDX6 and a rare variant of IL12A, we
could not confirm the signal of association in our sample,
ruling out independent replication. When a meta-analysis
was performed, no association was observed for DDX6
rs7130875, but the original association observed for IL12A
rs77583790 was strengthened, thus confirming this latter
locus.
As compared with linkage analyses, association studies
have much less power in cases of different mutations acting
in different families; however, they are far more sensitive
than family studies to study complex polygenic associations.
In such diseases, the phenotype is associated with the joint
affects of several weakly contributing variants across
various loci. However, GWASs have received criticism and
skepticism because of the structure of the knowledge it has
produced, which contrasts with the highly penetrant
Mendelian genetic discoveries. Indeed, interpreting and
understanding the molecular mechanisms related to non-
coding variants are challenging given the diversity of non-
coding functions, the incomplete annotation of regulatory
elements, and the probable still uncovered mechanisms of
regulatory control. If some studies, through extensive
experimental work, uncovered some molecular mecha-
nisms responsible for disease association [27], far more
disease-associated variants remain uncharacterized. How-
ever, expanding the catalog of non-coding variants associ-
ated with human diseases is still meaningful. Indeed,
several promises have emerged; for example, the application
to GWAS data of gene-set enrichment analyses has
provided meaningful data regarding some regulatory mech-
anisms [28]. The new and complementary approaches,
including integration of annotation, higher resolution, andfunctional maps, may provide the basis for deciphering the
effects of non-coding variants in pathways or cell types tak-
ing into account the weak additive interactions discovered
on GWAS and the potential epistatic interactions between
the variants. Such complementary strategies might finally
improve the interpretation of disease-associated variants
and may help identify the most likely causal regulator.
These post-genomic functional studies are eagerly awaited
in order to try to elucidate the biological consequences of
non-coding variants.
Herein, we identified a novel epistatic interaction
between NF-κB and IRF8 genes, which may contribute to
SSc susceptibility. This gene-gene interaction might explain
the small OR obtained in our genetic association studies,
which increase our understanding of missing heritability.
Although the biological consequences of this interaction
remain unknown, our results highlight the importance of
combined analysis of genetic associations in candidate gene
studies.
Taken together, our data support the shared genetic bases
that are involved in SSc and PBC susceptibility. Of note, we
highlight the participation of genes that are related to anti-
gen recognition mediated by TLR and B cells, emphasizing
their role in SSc susceptibility. In our mRNA expression
analysis, we used resting PBMCs; hence, it is suggested that
further studies use PBMC activators to enhance the expres-
sion signal.
Conclusions
Although the exact role played by PLCL2, NF-κB, and IRF8
is yet to be determined, we provide convincing evidence
which highlights the importance of these genes in SSc. Iden-
tification of new variants, interactions between unlinked
loci, and epistatic effects may help us to better understand
the intricate processes of heterogeneity of AIDs.
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